Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of TQH2722 injection for chronic rhinosinusitis with or without nasal polyps
CTR20241969Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis (CRS), sponsored by Nanjing Shunxin Pharmaceutical. Started Jul 2024; status: active.
02
Drugs
TQH2722
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on CTR20241969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241969.